Lower risk of cardiovascular events and death associated with initiation of SGLT-2 inhibitors versus sulphonylureas - Analysis from the CVD-REAL 2 study.
Su-Yen GohMikhail N KosiborodCarolyn Su Ping LamMatthew A CavenderShun KohsakaAnna NorhammarKåre Inge BirkelandReinhard W HollDídac MauricioNavdeep TangriJonathan E ShawMarcus ThuressonPeter FeniciDae-Jung Kimnull nullPublished in: Diabetes, obesity & metabolism (2023)